AIT THERAPEUTICS INC

Inactive Instrument

Analyst Reco. AIT Therapeutics Inc Other OTC

Equities

US50027L1070

End-of-day quote Other OTC Other stock markets
- ^USD	-

04-30	Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	MT
02-12	Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	04-30	MT
Truist Cuts Beyond Air's Price Target to $10 From $14, Maintains Buy Rating	11-14	MT
Piper Sandler Starts Beyond Air at Overweight With $10 Price Target	28/07/23	MT
Truist Adjusts Beyond Air's Price Target to $14 From $18, Keeps Buy Rating	21/07/23	MT
Roth MKM Cuts Beyond Air's Price Target to $12 From $14, Maintains Buy Rating	28/06/23	MT
Oppenheimer Cuts Beyond Air's Price Target to $10 From $16, Maintains Outperform Rating	23/06/23	MT
BTIG Research Initiates Coverage on Beyond Air With Buy Rating, $15 Price Target	15/06/23	MT
Oppenheimer Adjusts Beyond Air Price Target to $16 From $13, Maintains Outperform Rating	12/08/22	MT
Truist Securities Adjusts Beyond Air Price Target to $20 From $16, Maintains Buy Rating	29/06/22	MT
Ladenburg Thalmann Adjusts Beyond Air's Price Target to $23 From $17, Reiterates Buy Rating	29/06/22	MT
Oppenheimer Adjusts Beyond Air PT to $13 From $9, Maintains Outperform Rating	12/11/21	MT
Truist Securities Adjusts Beyond Air's Price Target to $16 From $12, Reiterates Buy Rating	12/11/21	MT
BEYOND AIR : Truist Securities Starts Beyond Air at Buy with $12 Price Target	28/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer